GBM102 GBM Model

GBM102-derived PDX model is at the forefront of preclinical Brain Cancer drug discovery. Its crucial role lies in its ability to accurately mimic patient responses, providing a reliable platform for evaluating the efficacy and safety of drug candidates. Researchers depend on GBM102 PDX to make informed decisions, prioritize promising therapies, and streamline their path to clinical trials. This model significantly accelerates the drug development process by identifying viable treatment options and optimizing their potential for Brain Cancer patients.

Model Details

Cancer Location: Intracranial
Cancer Type: Brain Cancer
Model Name: GBM102
Mouse Strain: Nu/Nu
Treatment Data Available: Chemotherapy (Temozolomide), Radiation (2Gy)
WES: Yes
RNAseq: Yes
Methylation: Yes
PDX Treatment: Yes
Patient Treatment History: Yes

GBM102 Survival

Survival of orthotopic intracranial implanted  GBM102 in Nu/Nu mice  (n=5)

Request Additional GBM Model Data

Contact Us

Get Started.

Have questions about how TD2 can assist with your regulatory needs? Reach out to our
expert staff today to get started.

Skip to content